ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Nutrition and Supplements
Melatonin is also a big immune system booster.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tareload" data-source="post: 220378"><p>[URL unfurl="true"]https://www.ncbi.nlm.nih.gov/books/NBK550972/[/URL]</p><p></p><p>The time of melatonin administration is critical, especially in chronic treatments, and the melatonin profile shows large interindividual variation; however, the profile of an individual is highly reproducible from day to day. Also, absorption, metabolism and excretion of melatonin vary between individuals and should be considered to get the desired clinical efficacy of the therapy. Ideally, although not feasible in a daily clinical practice, DLMO should be determined for each individual, and used as a timing reference for the prescription of melatonin. Alternatively, the time each individual goes to sleep could determine the time of administration of melatonin; it is advisable to take oral melatonin around 45 minutes to 1 hour before the usual bedtime (time to reach maximal plasma concentrations following oral immediate-release formulations). Moreover, the duration of the pharmacological profile should last until the usual wake time of the patient; thus, the type of pharmaceutical formulation (slow or fast release) is also an important consideration. Route of administration, as well as age, liver function and potential drug interactions (since melatonin is metabolized in the liver), may influence plasma melatonin levels and should be taken into account (<strong><a href="https://www.ncbi.nlm.nih.gov/books/NBK550972/#" target="_blank">95</a></strong>). <em><strong>Sensitivities and pharmacokinetics of melatonin vary between individuals, and a lower dose of 0.3-0.5 mg might be more effective than higher doses in many subjects.</strong></em></p><p><em></em></p><p><em></em></p><p><em>There is no general consensus regarding dosage. A wide range of dose formulations are available, and the usage varies depending on the clinical application. <strong>Low doses </strong></em><u><em><strong>0.1 to 0.3 mg/d that produce physiological melatonin concentrations</strong></em></u><em><strong> can be used for central clock synchronization;</strong> doses ranging from 0.6 to 5 mg/d for sleep disorders, or doses as high as 300 mg/d for neurodegenerative disorders (amyotrophic lateral sclerosis) (<a href="https://www.ncbi.nlm.nih.gov/books/NBK550972/#" target="_blank">96</a>,<a href="https://www.ncbi.nlm.nih.gov/books/NBK550972/#" target="_blank">97</a>). In most clinical trials or studies using melatonin,<strong> it is well accepted that in general melatonin lacks toxic adverse events, and it is a safe drug at most of the usual tested doses from 0.5 to 5 mg/d (<a href="https://www.ncbi.nlm.nih.gov/books/NBK550972/#" target="_blank">98</a>).</strong> Whether dosage should be changed in chronic melatonin treatment according to the annual season requires further investigation; further studies are needed on the undesirable consequences of melatonin suppression in the long term.</em></p><p><em></em></p><p><em>[ATTACH=full]20612[/ATTACH]</em></p></blockquote><p></p>
[QUOTE="tareload, post: 220378"] [URL unfurl="true"]https://www.ncbi.nlm.nih.gov/books/NBK550972/[/URL] The time of melatonin administration is critical, especially in chronic treatments, and the melatonin profile shows large interindividual variation; however, the profile of an individual is highly reproducible from day to day. Also, absorption, metabolism and excretion of melatonin vary between individuals and should be considered to get the desired clinical efficacy of the therapy. Ideally, although not feasible in a daily clinical practice, DLMO should be determined for each individual, and used as a timing reference for the prescription of melatonin. Alternatively, the time each individual goes to sleep could determine the time of administration of melatonin; it is advisable to take oral melatonin around 45 minutes to 1 hour before the usual bedtime (time to reach maximal plasma concentrations following oral immediate-release formulations). Moreover, the duration of the pharmacological profile should last until the usual wake time of the patient; thus, the type of pharmaceutical formulation (slow or fast release) is also an important consideration. Route of administration, as well as age, liver function and potential drug interactions (since melatonin is metabolized in the liver), may influence plasma melatonin levels and should be taken into account ([B][URL='https://www.ncbi.nlm.nih.gov/books/NBK550972/#']95[/URL][/B]). [I][B]Sensitivities and pharmacokinetics of melatonin vary between individuals, and a lower dose of 0.3-0.5 mg might be more effective than higher doses in many subjects.[/B] There is no general consensus regarding dosage. A wide range of dose formulations are available, and the usage varies depending on the clinical application. [B]Low doses [/B][/I][U][I][B]0.1 to 0.3 mg/d that produce physiological melatonin concentrations[/B][/I][/U][I][B] can be used for central clock synchronization;[/B] doses ranging from 0.6 to 5 mg/d for sleep disorders, or doses as high as 300 mg/d for neurodegenerative disorders (amyotrophic lateral sclerosis) ([URL='https://www.ncbi.nlm.nih.gov/books/NBK550972/#']96[/URL],[URL='https://www.ncbi.nlm.nih.gov/books/NBK550972/#']97[/URL]). In most clinical trials or studies using melatonin,[B] it is well accepted that in general melatonin lacks toxic adverse events, and it is a safe drug at most of the usual tested doses from 0.5 to 5 mg/d ([URL='https://www.ncbi.nlm.nih.gov/books/NBK550972/#']98[/URL]).[/B] Whether dosage should be changed in chronic melatonin treatment according to the annual season requires further investigation; further studies are needed on the undesirable consequences of melatonin suppression in the long term. [ATTACH type="full" alt="1648480547270.png"]20612[/ATTACH][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Nutrition and Supplements
Melatonin is also a big immune system booster.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top